<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613387</url>
  </required_header>
  <id_info>
    <org_study_id>ZP8396-21038</org_study_id>
    <nct_id>NCT05613387</nct_id>
  </id_info>
  <brief_title>A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants</brief_title>
  <official_title>A Randomized, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a single-centre, randomised and double-blind within cohorts, placebo-controlled,&#xD;
      sequential multiple ascending dose trial in normal weight and overweight but otherwise&#xD;
      healthy subjects randomised to subcutaneous administration of ZP8396 or placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research study will investigate the safety and tolerability of ZP8396 in healthy study&#xD;
      participants. In addition, the study will investigate how ZP8396 works in the body&#xD;
      (pharmacokinetics and pharmacodynamics).&#xD;
&#xD;
      Participants will receive 6 once-weekly doses as an injection under the skin (subcutaneous,&#xD;
      s.c.).&#xD;
&#xD;
      Participants will have 14 visits with the study team. 6 of these visits consists of overnight&#xD;
      stays of different duration (2-4 nights) at the study site. For each participant, the study&#xD;
      will last up to 116 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2022</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A single-centre, placebo-controlled, double-blind (within cohorts), randomised multiple ascending dose trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From dosing (Day 1) to end of trial (Day 92)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (AUCτ)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Area under the plasma concentration-time curve over a dosing interval. Samples will be taken at set time points throughout the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (AUCinf)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to infinity. Samples will be taken at set time points throughout the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (AUClast)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration. Samples will be taken at set time points throughout the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (Cmax)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Maximum (peak) plasma drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (tmax)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Time to reach maximum (peak) plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (λz)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (t½)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (Vz/f)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (CL/f)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Apparent total clearance of the drug from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ZP8396 (Ctrough)</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Trough concentration measured pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio for AUCτ</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Accumulation Ratio for AUCτ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio for Cmax</measure>
    <time_frame>Day 1 (pre-dose) to Day 92</time_frame>
    <description>Accumulation Ratio for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (Cmax acetaminophen)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Maximum acetaminophen concentration after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (Tmax acetaminophen)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Time to maximum acetaminophen concentration after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (AUCacetaminophen, 0-60 min)</measure>
    <time_frame>0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Area under the acetaminophen concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (AUCacetaminophen, 0-240 min)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Area under the acetaminophen concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (Emax, Plasma Glucose [PG])</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Maximum PG concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (Tmax, Plasma Glucose [PG])</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Time to maximum PG concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (AUE, Plasma Glucose [PG], 0-60 min)</measure>
    <time_frame>0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Area under the acetaminophen concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (AUE, Plasma Glucose [PG], 0-240 min)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Area under the acetaminophen concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (Emax, insulin)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Maximum insulin concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (Tmax, insulin)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Time to maximum insulin concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (AUEinsulin,0-60 min)</measure>
    <time_frame>0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Area under the insulin concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (AUEinsulin,0-240 min)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Area under the insulin concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (Emax, glucagon)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Maximum glucagon concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (Tmax, glucagon)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Time to maximum glucagon concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (AUEglucagon,0-60 min)</measure>
    <time_frame>0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Area under the glucagon concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of ZP8396 (AUEglucagon,0-240 min)</measure>
    <time_frame>0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40</time_frame>
    <description>Area under the glucagon concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Overweight</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ZP8396</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 dose cohorts are planned with 10 subjects in each; 7 participants in each cohort will receive active treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (ZP8396)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In each of the 3 dose cohorts, 3 subjects will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP8396</intervention_name>
    <description>Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.</description>
    <arm_group_label>ZP8396</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Placebo (ZP8396)</intervention_name>
    <description>Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).</description>
    <arm_group_label>Placebo (ZP8396)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) between 21.0 and 29.9 kg/m^2, both inclusive&#xD;
&#xD;
          -  Glycosylated hemoglobin (HbA1c) below 5.7 percent&#xD;
&#xD;
          -  Further inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of metabolic diseases more frequently associated with obesity, e.g.&#xD;
             type-2-diabetes mellitus, hypertension, dyslipidemia, heart disease or stroke&#xD;
&#xD;
          -  Systolic blood pressure below 90 mmHg or above139 mmHg and/or diastolic blood pressure&#xD;
             below 50 mmHg or above 89 mmHg&#xD;
&#xD;
          -  Symptoms of arterial hypotension&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zealand Pharma A/S</last_name>
    <role>Study Director</role>
    <affiliation>Zealand Pharma A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>+45 88 77 36 00</phone>
    <email>clinicaltrials@zealandpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <state>North Rhine-Westphalia</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Matern</last_name>
      <phone>+4921314018</phone>
      <phone_ext>493</phone_ext>
      <email>simone.matern@profil.com</email>
    </contact>
    <contact_backup>
      <last_name>Elke Gurschke</last_name>
      <phone>+4921314018</phone>
      <phone_ext>411</phone_ext>
      <email>regulatory@profil.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrike Hövelmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 28, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

